Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT05305547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05305547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Completed
Start date
August 3, 2022
Completion date
May 24, 2024
Enrollment
2,093 (actual)
Sites
196

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection